Table 1 Summary of clinical studies on monoclonal antibodies for eosinophilic esophagitis (EoE) treatment
From: Eosinophilic esophagitis in children: doubts and future perspectives
Study | Design | Drug | Target | Population |
|---|---|---|---|---|
Assa’ad et al. [70] | Randomized double-blind parallel group | Mepolizumab | IL-5 | Children (n = 59) |
Otani et al. [71] | Randomized double-blind single arm | Mepolizumab | IL-5 | Children (n = 43) |
Spergel et al. [72] | Randomized double-blind, placebo control | Reslizumab | IL-5 | Children (n = 226) |
Arasi et al. [77] | Case report | Omalizumab | IgE | Child (n = 1) |
Rocha et al. [73] | Case series | Omalizumab | IgE | Children (n = 2) |
Loizou et al. [79] | Non-randomized, open-label, single arm | Omalizumab | IgE | Children and adults (n = 15) |
Clayton et al. [78] | Randomized double-blind, placebo control | Omalizumab | IgE | Children and adults (n = 30) |
Rothemberg et al. [62] | Randomized double-blind, placebo control | QAX576 | IL-13 | Adults (n = 25) |
Straumann et al. [85] | Non-randomized, open-label, single arm | Infliximab | TNF-alpha | Adults (n = 3) |